The UK and US have hammered out a significant bilateral deal that will maintain no levies on British medicine shipments entering the US market.
Key Provisions of the Deal
In exchange for the tariff guarantee, the UK has agreed to increase spending on pharmaceuticals through the National Health Service (NHS). This move ensures that tariffs on these key exports will be held at zero for a timeframe of three years.
This development is in response to earlier warnings to significantly raise tariffs on branded pharmaceutical products, with potential rates floated up to 100%.
"This deal with the United Kingdom reinforces the international landscape for new treatments and brings long-overdue balance to U.S.–U.K. medicine commerce," a release said.
Trade Significance
Drugs constitute one of the the United Kingdom's most significant exports to the United States, which is by far the largest buyer for large companies like GSK and AstraZeneca.
Trade data show that in the one-year period leading up to the third quarter, the UK exported drugs valued at £11.1bn to the US. This figure made up a significant portion of total UK exports in that span.
"This guarantee safeguards jobs, boosts investment and facilitates the UK to establish itself as a global hub for biotech and pharma," the Business and Trade Secretary stated.
Specific UK Commitments
The deal includes several notable changes from the UK:
- Higher Cost Ceiling: The UK will lift the affordability limit at which it judges new treatments to be prohibitively costly by twenty-five percent.
- Increased NHS Spending: There is a goal to double total public funding on treatments from 0.3% of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Refund Ceiling: The percentage pharmaceutical firms must refund to the NHS to prevent overspending will be limited at fifteen percent. Last year, rebates topped twenty percent.
Recent Tensions
The pact follows a long-running tension between the sector and the British authorities over medicine costs and regulatory access.
This friction were heightened by arguments that US patients were charged significantly more for the equivalent treatments than patients in the UK and Europe.
In recent months, several large drug company projects in the UK have been halted or scrapped, while substantial expansions have been announced toward projects in the United States.
A senior figure publicly accepted that the NHS must increase expenditure on drugs, noting that its budget allocation on drugs had shrunk as a proportion of its overall budget over the previous ten-year period.
